



DR. FRESH ASSETS LIMITED

(Formerly known as Sunehari Exports Limited)

Regd. Off.: B-1/E-24, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi- 110044

Phone: 91-11-41679238, 26940969

E-mail: drfresh@drfreshassets.com website: www.drfreshassets.com

CIN: L74899DL1990PLC042302

February 14, 2023

**To,
Metropolitan Stock Exchange of India Limited**

Building A, Unit-205(A), 2nd floor,
Piramal Agastya Corporate Park,
Kamani Junction, LBS Road, Kurla (West),
Mumbai – 400 070

Ref: Symbol: DRFRESH

**Sub: Un-Audited Standalone and Consolidated Financial Results for the
Quarter and Nine Months ended December 31, 2022**

Dear Sir/Ma'am,

Pursuant to regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, we wish to inform you that the Un-Audited Standalone and Consolidated Financial Results ('Financial Results') of the Company for the Quarter and Nine Months ended December 31, 2022 were approved by the Board of Directors of the company in its meeting held today i.e. Tuesday, 14th February, 2023.

Please take the above information on record.

Please find the enclosed herewith the copy of Financial Results of the Company along with the Limited Review Report thereon.

Yours faithfully,

For Dr Fresh Assets Ltd


Vijay Prakash Pathak
Whole Time Director
DIN: 07081958



Encl:a/a

Independent Auditors Limited Review Report on Unaudited year to date Financial Results of DR FRESH ASSETS LIMITED under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015, as amended

To
The Board of Directors of
Dr Fresh Assets Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Dr Fresh Assets Limited for the quarter ended 31st December, 2022 & for the period from 1st April 2022 to 31st December, 2022 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, is the responsibility of the Company's Management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on these financial statements based on our review
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. The comparative IND AS financial information of the Company for the corresponding quarter and nine month ended 31st December, 2021 and for the quarter ending June, 2022 provided to us by the management, were reviewed by the predecessor auditor, who expressed an unmodified conclusion on that financial information. Also, the IND AS financial statements of the Company for the year ended 31st March 2022, provided to us by the management, were audited by predecessor auditor who expressed an unmodified opinion on those financial information.

For B. K. SHROFF & Co.
Chartered Accountants
Firm Registration No. 302166E

Kavita Nangia

(KAVITA NANGIA)
PARTNER

Membership Number: 090378

Place: New Delhi
Date: 14.02.2022
UDIN: 23090378BGXOGE3955





DR. FRESH ASSETS LIMITED

(Formerly known as Sunehari Exports Limited)
 Regd. Off.: B-1/E-24, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi- 110044
 Phone: 91-11-41679238, 26940989
 E-mail: drfresh@drfreshassets.com website: www.drfreshassets.com
 CIN: L74899DL1990PLC042302

UNAUDITED STANDALONE FINANCIAL RESULTS (REVIEWED) FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(All figures are Rs in Lakhs except EPS)

Sl. No	Particulars	Standalone Quarter Ended			Standalone Nine Months Ended		Standalone Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
	REVENUE :						
1	Revenue from Operations	31.13	28.99	26.55	271.84	194.00	633.29
2	Other Income	57.99	37.53	11.49	118.20	166.59	168.95
3	TOTAL REVENUE (1+2)	89.12	66.52	40.04	390.04	360.59	802.24
4	EXPENSES :						
a	Purchase Traded Goods	7.98	7.83	23.67	29.16	180.46	182.74
b	Changes in Inventory of Traded Goods	(1.77)	3.96	(8.93)	37.91	(24.59)	87.64
c	Cost of Material Consumed	-	-	-	-	-	-
d	Employee Benefits Expense	12.39	11.52	12.17	34.02	31.18	40.75
e	Finance Costs	2.03	1.86	1.46	5.76	4.11	5.95
f	Depreciation	3.75	3.75	3.33	11.24	10.02	13.40
g	Other Expenses	15.95	(43.53)	21.52	41.68	47.48	69.94
	TOTAL EXPENSES	40.33	(14.62)	63.23	169.78	248.67	410.42
5	Profit / (Loss) before Exceptional and Extraordinary Items & Tax (3-4)	48.79	81.14	(13.18)	230.26	111.92	391.82
6	Exceptional Items	-	-	-	-	-	-
7	Profit / (Loss) before Tax	48.79	81.14	(13.18)	230.26	111.92	391.82
8	Provision for Taxation						
a	Current Taxes	(4.48)	9.09	-	31.08	2.50	55.25
b	Earlier Year Taxes	0.83	(0.04)	-	0.79	-	-
c	Deferred Tax (Assets)/ Liabilities	6.44	14.14	(7.15)	9.26	20.33	34.74
9	Add: MAT Credit Entitlement	(9.69)	(0.51)	0.00	(17.15)	2.50	(12.75)
9	Net Profit / (Loss) After Tax (7-8+9)	36.31	57.44	(6.03)	171.99	91.59	289.08
10	Other Comprehensive Income (Net of Tax)						
a	Item that will not be reclassified to profit or loss	13.24	264.42	11.93	232.00	76.25	372.20
b	Item that will be reclassified to profit or loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period	49.55	321.85	5.90	403.99	167.84	661.28
12	Paid up Equity Share Capital (Face Value Rs. 10/- Per Share)	1077.91	538.96	538.96	1077.91	538.96	538.96
13	Other Equity						3758.98
14	Basic and Diluted EPS for the period, for the year to date and for the previous year (Rs.) *	0.33	0.53	(0.06)	1.58	0.84	2.66

* During the quarter 1:1 bonus issue made, accordingly EPS for previous periods, year has been adjusted.



UNAUDITED STANDALONE SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(All figures are Rs in Lakhs except EPS)

Sl. No	Particulars	Standalone Quarter Ended			Standalone Nine Months Ended		Standalone Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
1	Segment Revenue						
	Sales & Other Operating Revenue						
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	15.61	13.95	14.01	226.28	153.66	578.15
	Real Estate Business Related Activities	15.52	15.05	13.95	45.57	40.14	55.14
	Others Unallocable	-	-	-	-	-	-
	TOTAL OPERATING REVENUE	31.13	28.99	28.66	271.84	194.00	633.29
2	Segment Results						
	(Profit +/- Loss - Before Interest & Tax)						
	Oral Care Activities	3.16	(3.31)	(3.47)	(2.57)	(14.74)	(21.37)
	Trading Activities (including Gold)	8.88	1.54	0.24	158.50	(1.31)	297.44
	Real Estate Business Related Activities	13.94	13.63	9.37	40.66	33.08	41.88
	Others Unallocable	24.85	71.14	(17.86)	39.44	99.01	80.02
	Less: Interest(Net) Expenses	60.82	82.99	(11.72)	236.03	116.03	397.77
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	-	-	-	-	-	-
	Real Estate Business Related Activities	0.22	0.22	0.60	0.68	1.38	1.84
	Others Unallocable	1.81	1.84	0.86	5.11	2.73	4.11
	Less: Other Unallocable Expenditure net off Unallocable Income	-	-	-	-	-	-
	TOTAL PROFIT BEFORE TAX	48.79	81.14	(13.18)	230.26	111.92	391.82
3	Capital Employed (Segment Assets - Segment Liabilities)						
	a) Segment Assets						
	Oral Care Activities	38.94	39.89	42.72	38.94	42.72	41.78
	Trading Activities (including Gold)	1403.01	1379.47	1529.04	1403.01	1529.04	1462.94
	Real Estate Business Related Activities	2603.44	3031.99	1920.73	2603.44	1920.73	2630.66
	Others Unallocable	1823.21	1360.50	1287.99	1823.21	1287.99	1280.09
	Total Segment Assets (a)	5868.60	5811.85	4780.48	5868.60	4780.48	5415.47
	b) Segment Liabilities						
	Oral Care Activities	249.29	249.94	248.40	249.29	248.40	249.66
	Trading Activities (including Gold)	1.70	1.85	-	1.79	-	10.12
	Real Estate Business Related Activities	247.04	247.04	246.96	247.04	246.96	247.00
	Others Unallocable	654.45	656.53	476.51	654.45	476.51	606.65
	Total Segment Liabilities (b)	1162.57	1166.37	971.87	1162.57	971.87	1113.43
	TOTAL CAPITAL EMPLOYED IN SEGMENTS (a - b)	4706.04	4656.49	3808.61	4706.04	3808.61	4302.06

Notes :

- The above standalone financial results have been reviewed by the audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2023.
- These financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- In line with the requirements of Regulation 47(2) of the Listing Regulations, 2015, the results are available on the stock exchanges website (i.e. www.mcx-sx.com) and on the company's website (i.e. www.dr.freshassets.com).
- During the quarter the company allotted 53,89,563 Equity Shares of Rs. 10/- each by way of bonus issue (record date 07.10.2022) in the ratio of 1: 1.
- Figures of the previous quarter have been regrouped wherever necessary.

Place : DELHI
Date : 14.02.2023



Per Dr. Fresh Assets Limited

Vijay Prakash Pathak
Whole Time Director
DIN-07081958



Independent Auditor's Review Report on Consolidated Unaudited year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Dr Fresh Assets Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr Fresh Assets Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 31st December, 2022 and the period from 1st April, 2022 to 31st December, 2022 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities:
 - (i) Dr Fresh Assets Limited (Holding Company)
 - (ii) Reverse Age Health Services Pvt Ltd (Subsidiary)
 - (iii) S5 Property Private Limited (Subsidiary)
 - (iv) Dr Fresh Commercial Land Development Pvt Ltd (Subsidiary)
 - (v) SEL International Pte Limited (Subsidiary)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matter –

We draw attention to

- a) Note No – 3 to the consolidated financial results, relating to 2 subsidiaries whose net worth has eroded, their accounts have been prepared as a going concern.

Our opinion is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial results of one Foreign subsidiary whose Results have not been reviewed, as Review/Audit is not mandatory in the country of its incorporation, its interim financial results reflect total revenue of Rs. 48.00 Lac & Rs. 128.32 Lac, total Net Profit after tax of Rs. 28.35 Lac & Rs. 0.64 Lac and total comprehensive income of Rs. 28.35 Lac & Rs. 0.64 Lac for the quarter ended 31st December, 2022 and for the period from 1st April, 2022 to 31st December, 2022 respectively as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial results are certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

For B. K. Shroff & Co
Chartered Accountants
Firm Registration No. 090378

Kavita Nangia

(KAVITA NANGIA)
PARTNER

Membership Number:-090378

Place: New Delhi

Date : 14.02.2023

UDIN: **23090378BGXOGF1388**





DR. FRESH ASSETS LIMITED

(Formerly known as Sunehri Exports Limited)

Regd. Off.: B-1/E-24, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi- 110044
Phone: 91-11-41679238, 26940969

E-mail: drfresh@drfreshassets.com website: www.drfreshassets.com
CIN: L74899DL1990PLC042302

UNAUDITED CONSOLIDATED FINANCIAL RESULTS (REVIEWED) FOR THE THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(All figures are Rs in Lakhs except EPS)

Sl. No.	Particulars	Consolidated Quarter Ended			Consolidated Nine Months Ended		Consolidated Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
	REVENUE :						
1	Revenue from Operations	96.87	122.99	39.52	440.99	3080.33	3654.54
2	Other Income	58.90	22.01	9.55	101.68	157.93	156.79
3	TOTAL REVENUE (1+2)	155.76	145.00	49.07	542.67	3238.26	3811.33
4	EXPENSES :						
a	Purchase Traded Goods	10.77	10.79	26.88	38.61	193.14	210.66
b	Changes in Inventory of Traded Goods	(4.61)	4.55	(8.17)	34.45	2330.00	2442.00
c	Cost of Material Consumed	-	-	-	-	-	-
d	Employee Benefits Expense	67.86	57.84	46.06	169.85	130.61	176.75
e	Finance Costs	2.69	2.06	4.96	8.76	60.92	84.04
f	Depreciation	4.43	4.43	4.03	13.28	12.05	16.10
g	Other Expenses	6.74	4.41	51.17	96.64	107.03	243.26
	TOTAL EXPENSES	87.87	84.98	126.73	361.60	2853.75	3172.81
5	Profit / (Loss) before Exceptional and Extraordinary items & Tax (3-4)	67.89	60.02	(77.66)	181.07	384.51	638.52
6	Exceptional Items	-	-	-	-	-	-
7	Profit / (Loss) before Tax	67.89	60.02	(77.66)	181.07	384.51	638.52
8	Provision for Taxation						
a	Current Taxes	(4.48)	9.09	-	31.08	82.50	115.97
b	Earlier Year Taxes	0.83	(1.91)	-	(1.08)	-	-
c	Deferred Tax (Assets)/ Liabilities	3.03	8.76	(13.89)	(4.00)	37.77	45.00
9	Add: MAT Credit Entitlement	(9.09)	(0.51)	0.00	(17.15)	2.50	(12.75)
9	Net Profit / (Loss) After Tax (7-8+9)	58.82	43.57	(63.77)	137.91	266.74	464.80
10	Other Comprehensive Income (Net of Tax)						
a	Item that will not be reclassified to profit or loss	(11.03)	264.43	11.93	230.55	94.63	261.95
b	Item that will be reclassified to profit or loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period	47.79	308.00	(51.84)	368.46	361.37	726.75
12	Paid up Equity Share Capital (Face Value Rs. 10/- Per Share)	1077.91	538.96	538.96	1077.91	538.96	538.96
13	Other Equity						3481.86
14	Basic and Diluted EPS for the period, for the year to date and for the previous year (Rs.) *	0.54	0.40	(0.59)	1.27	2.46	4.28

* During the quarter 1:1 bonus issue made, accordingly EPS for previous periods, year has been adjusted.



UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(All figures are Rs in Lakhs except EPS)

Sl. No	Particulars	Consolidated Quarter Ended			Consolidated Nine Months Ended		Consolidated Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
1	Segment Revenue						
	Sales & Other Operating Revenue						
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	31.79	26.34	24.83	263.40	205.75	640.11
	Real Estate Business Related Activities	15.52	15.05	13.95	45.57	2672.14	2667.14
	Others Unallocable	49.56	81.60	0.74	132.02	2.44	127.29
	TOTAL OPERATING REVENUE	96.87	122.99	39.52	440.99	3080.33	3654.54
2	Segment Results (Profit +/- Loss - Before interest & Tax)						
	Oral Care Activities	4.55	(4.70)	(3.47)	(2.57)	(14.74)	(21.37)
	Trading Activities (including Gold)	6.96	(7.38)	(20.66)	137.88	(13.13)	259.04
	Real Estate Business Related Activities	11.01	10.68	6.85	31.97	502.77	427.17
	Others Unallocable	48.08	64.40	(55.22)	22.57	(9.48)	57.72
	Less: Interest(Not) Expenses	70.59	62.99	(72.71)	189.84	466.42	722.66
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	0.02	-	-	0.04	-	0.07
	Real Estate Business Related Activities	0.86	1.32	4.09	3.63	76.23	79.86
	Others Unallocable	1.81	1.64	0.86	5.11	2.68	4.11
	Loss: Other Unallocable Expenditure net off Unallocable Income	-	-	-	-	-	-
	TOTAL PROFIT BEFORE TAX	67.89	60.03	(77.66)	181.07	384.51	638.52
3	Capital Employed (Segment Assets - Segment Liabilities)						
a)	Segment Assets						
	Oral Care Activities	38.94	39.89	42.72	38.94	42.72	41.78
	Trading Activities (including Gold)	1416.63	1391.44	1536.21	1416.63	1536.21	1464.98
	Real Estate Business Related Activities	3431.63	3864.10	3212.28	3431.63	3212.28	3602.02
	Others Unallocable	2239.91	2421.32	2204.05	2239.91	2204.05	2326.48
	Total Segment Assets (a)	7127.11	7716.74	6995.26	7127.11	6995.26	7437.26
b)	Segment Liabilities						
	Oral Care Activities	249.29	249.94	240.40	249.29	248.40	249.66
	Trading Activities (including Gold)	679.48	712.14	885.81	679.48	885.81	751.19
	Real Estate Business Related Activities	1223.95	1222.70	1478.53	1223.95	1478.53	1348.26
	Others Unallocable	554.99	1186.88	716.33	554.99	716.33	1063.22
	Total Segment Liabilities (b)	2707.71	3371.65	3329.06	2707.71	3329.06	3412.32
	TOTAL CAPITAL EMPLOYED IN SEGMENTS (a - b)	4419.40	4346.09	3666.20	4419.40	3666.20	4024.93

Notes :

- The above consolidated financial results have been reviewed by the audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2023.
- These financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- With respect to 2 Subsidiary Companies due to continuous losses, network of these companies has eroded. However, management is exploring the possibility to start any viable project and the accounts have been prepared on going concern basis.
- In line with the requirements of Regulation 47(2) of the Listing Regulations, 2015, the results are available on the stock exchanges website (i.e. www.nse-ix.com) and on the company's website (i.e. www.drfreshassets.com).
- During the quarter the company allotted 53,89,553 Equity Shares of Rs. 10/- each by way of bonus issue (record date 07.10.2022) in the ratio of 1: 1.
- Figures of the previous quarter have been regrouped wherever necessary.

Place : DELHI
Date : 14.02.2023



For Dr. Fresh Assets Limited

Vijay Prakash Pathak
Whole Time Director
DIN-07061998

